{"id":"panzyga","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Panzyga","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:57:32.261835+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:57:48.394055+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:57:37.988125+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Panzyga","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:57:39.566611+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"9306c5f7-ddf9-5190-d0c1-31ba9ca2d0e0","title":"PANZYGA (IMMUNE GLOBULIN INTRAVENOUS (HUMAN)) SOLUTION [OCTAPHARMA USA INC]"},"aiSummary":"Panzyga, marketed by Octapharma, is an immunoglobulin G (IgG) therapy primarily indicated for the treatment of immune thrombocytopenic purpura (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP). The drug's key strength lies in its well-established safety and efficacy profile, supported by robust clinical trial results. The primary risk to Panzyga's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generic alternatives.","ecosystem":[],"_scrapedAt":"2026-03-27T23:35:41.670Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:57:48.394122+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04153422","phase":"PHASE2","title":"IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2023-12-15","conditions":"Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy","enrollment":20},{"nctId":"NCT04508530","phase":"PHASE3","title":"Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)","status":"COMPLETED","sponsor":"Octapharma","startDate":"2021-06-30","conditions":"Pediatric Acute-Onset Neuropsychiatric Syndrome","enrollment":71},{"nctId":"NCT07220915","phase":"PHASE3","title":"Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections","status":"NOT_YET_RECRUITING","sponsor":"Octapharma","startDate":"2025-12","conditions":"Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions","enrollment":360},{"nctId":"NCT04502030","phase":"PHASE3","title":"Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia (\"PRO-SID\" Study)","status":"COMPLETED","sponsor":"Octapharma","startDate":"2020-10-05","conditions":"Chronic Lymphocytic Leukemia, Hypogammaglobulinemia","enrollment":247},{"nctId":"NCT04929236","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients","status":"RECRUITING","sponsor":"Octapharma","startDate":"2023-10-01","conditions":"Pediatric Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":30},{"nctId":"NCT03866798","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)","status":"TERMINATED","sponsor":"Octapharma","startDate":"2020-01-21","conditions":"Chronic Immune Thrombocytopenia","enrollment":6},{"nctId":"NCT00033293","phase":"PHASE3","title":"Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-03-15","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma","enrollment":53},{"nctId":"NCT02303093","phase":"","title":"Non-Interventional Study on the Tolerability and Efficacy of IVIG","status":"COMPLETED","sponsor":"Octapharma","startDate":"2011-08-01","conditions":"Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG","enrollment":344},{"nctId":"NCT02638207","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy","status":"COMPLETED","sponsor":"Octapharma","startDate":"2017-09-27","conditions":"Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy","enrollment":142},{"nctId":"NCT03166527","phase":"PHASE3","title":"Panzyga in CIDP Administered at Different Infusion Rates","status":"UNKNOWN","sponsor":"Vera Bril","startDate":"2017-06-01","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":55,"reaction":"INFUSION RELATED REACTION"},{"count":48,"reaction":"HEADACHE"},{"count":47,"reaction":"DYSPNOEA"},{"count":46,"reaction":"URTICARIA"},{"count":43,"reaction":"CHILLS"},{"count":42,"reaction":"RASH"},{"count":36,"reaction":"NAUSEA"},{"count":36,"reaction":"PRURITUS"},{"count":26,"reaction":"HYPERTENSION"},{"count":26,"reaction":"PYREXIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":8,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Panzyga","genericName":"Panzyga","companyName":"Octapharma","companyId":"octapharma","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":3},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:57:48.394122+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}